have demonstrated that both GPVI and GPIb blockade protect from stroke in aged mice, mice with diabetes mellitus as well as hypertensive mice, suggesting that targeting GPVI or GPIb may be a future therapeutic option for patients with accompanying common metabolic diseases (137). This evidence concerns the gene GP6 and Other metabolic disease.